MIDATECH PHARMA PLC-ADR (MTP) Stock Price & Overview

NASDAQ:MTP • US59564R5000

0.2851 USD
-0.06 (-18.52%)
At close: Mar 24, 2023
0.2801 USD
-0.01 (-1.75%)
After Hours: 3/24/2023, 8:00:00 PM

The current stock price of MTP is 0.2851 USD. Today MTP is down by -18.52%. In the past month the price decreased by -47.19%. In the past year, price decreased by -93.38%.

MTP Key Statistics

52-Week Range0.2851 - 5.25
Current MTP stock price positioned within its 52-week range.
1-Month Range0.2851 - 0.5698
Current MTP stock price positioned within its 1-month range.
Market Cap
1.977M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.96
Dividend Yield
N/A

MTP Stock Performance

Today
-18.52%
1 Week
-20.39%
1 Month
-47.19%
3 Months
-60.41%
Longer-term
6 Months -89.63%
1 Year -93.38%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

MTP Stock Chart

MIDATECH PHARMA PLC-ADR / MTP Daily stock chart

MTP Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to MTP. When comparing the yearly performance of all stocks, MTP is a bad performer in the overall market: 99.03% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
MTP Full Technical Analysis Report

MTP Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to MTP. Both the profitability and financial health of MTP have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
MTP Full Fundamental Analysis Report

MTP Earnings

Next Earnings DateApr 24, 2023
Last Earnings DateN/A
PeriodQ2 / 2022
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
MTP Earnings History

MTP Forecast & Estimates


Analysts
Analysts45.71
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
MTP Forecast & Estimates

MTP Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

MTP Financial Highlights

Over the last trailing twelve months MTP reported a non-GAAP Earnings per Share(EPS) of -0.96. The EPS increased by 58.43% compared to the year before.


Income Statements
Revenue(TTM)645.00K
Net Income(TTM)-5.37M
Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity 0.07
Chartmill High Growth Momentum
EPS Q2Q%37.63%
Sales Q2Q%16.71%
EPS 1Y (TTM)58.43%
Revenue 1Y (TTM)11.98%
MTP financials

MTP Ownership

Ownership
Inst OwnersN/A
Shares6.93M
Float7.21M
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
MTP Ownership

MTP Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.3402.17B
AMGN AMGEN INC16.45203.213B
GILD GILEAD SCIENCES INC16.81182.029B
VRTX VERTEX PHARMACEUTICALS INC25.75117.075B
REGN REGENERON PHARMACEUTICALS16.5182.631B
ALNY ALNYLAM PHARMACEUTICALS INC43.2142.915B
INSM INSMED INC N/A30.852B
NTRA NATERA INC N/A29.086B
BIIB BIOGEN INC11.7227.626B
UTHR UNITED THERAPEUTICS CORP17.9423.193B
MRNA MODERNA INC N/A22.014B
EXAS EXACT SCIENCES CORP340.0819.797B
RVMD REVOLUTION MEDICINES INC N/A19.775B

About MTP

Company Profile

MTP logo image Midatech Pharma Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 20 full-time employees. The company went IPO on 2014-12-08. The firm is focused on improving the bio-delivery and biodistribution of medicines. The firm's technologies include Q-Sphera, MidaSolve and MidaCore. Q-Sphera technology focusses on long acting injectables using three-dimensional (3D) printing technology. MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility at biological potential of Hydrogen (pH) extending available routes of administration, including direct-to-tumor delivery. The company has a pipeline of approximately 10 earlier stage programmes, which includes MTD211 (Schizophrenia, MDD), MTD219 (Prophylaxis, transplant rejection), MTX223, MTX213, MTX214, MTX110 (Glioblastoma), MTX110 (Brain Cancer in Children (DIPG)), MTX110 (Medulloblastoma) and MTX114 (Psoriasis).

Company Info

IPO: 2014-12-08

MIDATECH PHARMA PLC-ADR

Oddfellows Hse, 19 Newport Road

Abingdon OXFORDSHIRE CF24 0AA GB

CEO: Stephen Stamp

Employees: 20

MTP Company Website

Phone: 4401235888300.0

MIDATECH PHARMA PLC-ADR / MTP FAQ

Can you describe the business of MIDATECH PHARMA PLC-ADR?

Midatech Pharma Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 20 full-time employees. The company went IPO on 2014-12-08. The firm is focused on improving the bio-delivery and biodistribution of medicines. The firm's technologies include Q-Sphera, MidaSolve and MidaCore. Q-Sphera technology focusses on long acting injectables using three-dimensional (3D) printing technology. MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility at biological potential of Hydrogen (pH) extending available routes of administration, including direct-to-tumor delivery. The company has a pipeline of approximately 10 earlier stage programmes, which includes MTD211 (Schizophrenia, MDD), MTD219 (Prophylaxis, transplant rejection), MTX223, MTX213, MTX214, MTX110 (Glioblastoma), MTX110 (Brain Cancer in Children (DIPG)), MTX110 (Medulloblastoma) and MTX114 (Psoriasis).


What is the current price of MTP stock?

The current stock price of MTP is 0.2851 USD. The price decreased by -18.52% in the last trading session.


Does MIDATECH PHARMA PLC-ADR pay dividends?

MTP does not pay a dividend.


What is the ChartMill technical and fundamental rating of MTP stock?

MTP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the Price/Earnings (PE) ratio of MIDATECH PHARMA PLC-ADR (MTP)?

MIDATECH PHARMA PLC-ADR (MTP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.96).


What is the next earnings date for MTP stock?

MIDATECH PHARMA PLC-ADR (MTP) will report earnings on 2023-04-24.